NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06988488 2026-02-02
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06383572 2025-12-23
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting